Core Viewpoint - Johnson & Johnson is highlighted as a potential buying opportunity despite recent market sell-offs, particularly due to its FDA approval for a new oral treatment for plaque psoriasis, which could significantly impact its market position [1][3]. Company Overview - Johnson & Johnson develops and sells healthcare products, including pharmaceuticals and medical technologies, with a focus on immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [3]. Recent Developments - The company received FDA approval for ICOTYDE, an oral treatment for moderate to severe plaque psoriasis, which is expected to compete strongly against existing injectable treatments [3]. - The market response to the FDA approval was muted, with the stock price declining by 0.35% despite the positive news, indicating a potential buying opportunity [3]. Market Potential - The total addressable market for the new oral treatment is substantial, with expectations that it could capture significant market share from AbbVie's Skyrizi, which generated over $17.5 billion in sales this year [3]. - Management estimates peak sales for the new drug could reach $5 billion, although some analysts believe this figure is conservative [3]. Investment Perspective - The current market conditions, particularly the oil-shock-driven sell-off, have created a favorable environment for investors to consider buying Johnson & Johnson stock, as the company's fundamentals remain strong [1][3]. - The company is characterized as a "textbook slowdown stock," suggesting resilience against broader market fluctuations [3].

Market Overview - The ongoing oil-shock-driven sell-off is significantly impacting the stock market, with rising oil prices leading to lower stock valuations [1] - The market is expected to continue its downward trend until the resolution of the war, which is contributing to inflation and higher interest rates [5] Economic Indicators - Key economic reports, including the JOLTS report and retail sales data, are anticipated to influence the Federal Reserve's decisions regarding interest rates [2][3] - The incoming Fed chief, Kevin Warsh, is looking for signs of job losses and weaker retail sales to justify potential rate cuts [3][4] Company Highlights Johnson & Johnson (NYSE: JNJ) - Johnson & Johnson is viewed as a strong investment opportunity, especially following the FDA approval of its oral treatment for moderate to severe plaque psoriasis, which could significantly impact its market position [9][10] - The stock has shown volatility, dropping from $140 to $230 rapidly, indicating potential for recovery and growth [9] - The new drug is projected to achieve peak sales of $5 billion, with some analysts suggesting this estimate may be conservative [10] Meta Platforms, Inc. (NASDAQ: META) - Meta is currently facing legal challenges that have negatively impacted its stock value, but these issues are not expected to affect its long-term earnings [11][12] - The company has lost significant market value due to recent court cases, highlighting the volatility associated with legal risks in the tech sector [11]

Core Insights - Johnson & Johnson (J&J) has a robust R&D pipeline focusing on immunology, oncology, and neuroscience, with significant advancements and approvals expected to drive growth through the latter half of the decade [1][10] R&D and Product Approvals - In 2025, J&J received approvals for Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis, marking key milestones in its pipeline [1][10] - The FDA approved Icotyde (icotrokinra), an oral treatment for moderate-to-severe plaque psoriasis, co-developed with Protagonist Therapeutics, enhancing J&J's portfolio [2][4] - Inlexzoh is a novel drug-releasing system for bladder cancer, while nipocalimab is being evaluated for various immune-mediated conditions, indicating its potential as a versatile treatment option [3][5] Market Potential and Sales Growth - J&J's new cancer drugs, including Carvykti, Tecvayli, and Talvey, generated $3 billion in sales in 2025, contributing to overall revenue growth [6][10] - The company anticipates that 10 of its new products could achieve peak sales of $5 billion, with expectations for a more significant impact from new products in 2026 compared to 2025 [7][8] Financial Performance and Valuation - J&J's shares have outperformed the industry, rising 47.1% over the past year compared to the industry's 9.5% increase [11] - The company's shares are currently trading at a price/earnings ratio of 20.42, higher than the industry average of 16.75, indicating a slightly expensive valuation [12] - The Zacks Consensus Estimate for 2026 earnings remains stable at $11.54 per share, with a slight increase for 2027 earnings from $12.33 to $12.44 [13][14]

Core Insights - Eli Lilly (LLY) and AbbVie (ABBV) are prominent U.S. drugmakers with strong market positions and diverse therapeutic portfolios, including immunology, oncology, and neuroscience [1][2] - Lilly's success is driven by its GLP-1 drugs, Mounjaro and Zepbound, which accounted for over 50% of its total revenues in 2025 [3][4] - AbbVie has successfully transitioned from the loss of exclusivity of Humira by launching new immunology drugs, Skyrizi and Rinvoq, which generated $26 billion in sales in 2025 [12][13] Summary of Eli Lilly - Mounjaro and Zepbound generated combined sales of $36.5 billion in 2025, representing around 56% of total revenues [4][10] - Lilly's new drugs and obesity pipeline, including orforglipron, are expected to drive sales growth in 2026 [5][10] - The company is investing in a broad obesity pipeline with various oral and injectable medications [6][7] - Despite strong growth prospects, Lilly faces challenges such as declining product prices and rising competition in the GLP-1 market [11] Summary of AbbVie - AbbVie has effectively managed the impact of Humira's loss of exclusivity by launching Skyrizi and Rinvoq, which are expected to generate over $31 billion in sales in 2026 [12][13] - The neuroscience portfolio contributed to a 20% increase in sales, reaching $10.8 billion in 2025 [14] - AbbVie has been active in acquisitions to enhance its early-stage pipeline, investing over $5 billion in 2025 [15] - The company anticipates a revenue growth of approximately 9.5% in 2026, supported by strong performances from its new drugs [27][28] Financial Estimates and Valuation - The Zacks Consensus Estimate for Lilly's 2026 sales and EPS implies increases of 25.7% and 41.1%, respectively [17] - AbbVie's 2026 sales and EPS estimates suggest growth of 9.6% and 45.6%, respectively [19] - Lilly's stock has risen 9.2% over the past year, while AbbVie's stock has increased by 2.0% [22] - AbbVie appears more attractive from a valuation perspective, with a forward P/E ratio of 13.75 compared to Lilly's 25.12 [22][24]

Group 1: Company Overview - AbbVie (NYSE:ABBV) is an American pharmaceutical company based in Illinois, developing, manufacturing, and selling drugs for a wide range of medical issues, including treatments for various cancers and inflammatory diseases, as well as skincare products [4] Group 2: Recent Developments - AbbVie expanded its psychiatry pipeline by acquiring the psychedelic compound bretisilocin from Gilgamesh Pharmaceuticals for $1.2 billion in 2025, which is a Phase 2 psychedelic drug candidate aimed at treating major depressive disorder [1] - AbbVie announced topline results from a Phase 1 study of ABBV-295, an amylin analog drug candidate targeting obesity, which were deemed competitive in the amylin class by William Blair [3] Group 3: Analyst Ratings - Guggenheim reiterated its Buy rating on AbbVie stock with a target price of $242, citing confidence in the growth outlook for Skyrizi and noting that AbbVie's overall business remains robust despite competition [2] - William Blair reaffirmed its Outperform rating on AbbVie stock, highlighting the potential of the company's obesity drug candidate following positive Phase 1 study results [3]

Core Insights - Johnson & Johnson (JNJ) received FDA approval for Icotyde, a once-daily oral peptide aimed at treating plaque psoriasis, which selectively blocks the interleukin-23 receptor (IL-23) [1] Company Overview - Icotyde was developed in collaboration with Brendan, who has a strong academic and professional background in organic synthesis and biotechnology [1] - Brendan's experience includes working at Merck and various biotech startups, and he is a co-founder of 1200 Pharma, which secured significant investment [1]

Core Insights - Johnson & Johnson (JNJ) announced FDA approval for Icotyde, a once-daily oral peptide for treating plaque psoriasis, which selectively blocks the interleukin-23 receptor (IL-23) [1] Company Overview - Icotyde was developed in collaboration with Brendan, who has a strong academic and professional background in organic synthesis and biotechnology [1] Industry Context - The approval of Icotyde represents a significant advancement in the treatment options available for plaque psoriasis, highlighting ongoing innovation in the biotechnology sector [1]

Group 1: AbbVie - AbbVie is recognized as a reliable dividend raiser and is classified as a Dividend King, having raised its dividend annually for at least 50 years, although it is a spinoff from Abbott Laboratories [2] - Concerns arose earlier this decade regarding AbbVie losing patent exclusivity on its blockbuster drug Humira, but the company proactively strengthened its pipeline and made strategic acquisitions, introducing next-generation treatments Skyrizi and Rinvoq [3] - In the fourth quarter, Skyrizi and Rinvoq generated nearly $7.4 billion in net revenue, accounting for 44% of AbbVie's total revenue for that period [4] - AbbVie's neuroscience portfolio, led by the antipsychotic treatment Vraylar, also showed strong performance with a year-over-year revenue increase of 18%, totaling just under $3 billion [4] - The company's free cash flow is robust, supporting its long-standing dividend policy with a quarterly payout of $1.73 per share, yielding 3.4% [5] Group 2: Bristol Myers Squibb - Bristol Myers Squibb faces similar patent expiration challenges as AbbVie, particularly with its cancer drugs Revlimid and Opdivo [6] - The company is focusing on innovation within its oncology lineup, which is part of its growth portfolio, resulting in a 16% year-over-year revenue increase in the fourth quarter, reaching almost $7.4 billion [6]

Core Viewpoint - AbbVie is currently underperforming in the market, down 11% this year compared to the S&P 500's 4% decline, amid broader bearish sentiment in the healthcare sector due to concerns over healthcare reform and government cuts [1][2] Company Performance - AbbVie's revenue reached $61.2 billion in 2025, reflecting a 9% increase from the previous year, with a strong upward growth trend observed in recent quarters [4] - The company has adapted to challenges, including the loss of patent protection for its top drug, Humira, by successfully launching new immunology drugs, Skyrizi and Rinvoq, which generated $25.9 billion in revenue last year [3] Market Position - AbbVie is trading at a forward price-to-earnings multiple of 14, significantly lower than the S&P 500 average of 21, indicating it may be undervalued [7] - The price-to-earnings-growth (PEG) multiple stands at 0.49, suggesting the stock is cheap relative to expected growth, as a PEG below 1.0 is considered favorable [8] Future Potential - Despite current market conditions, AbbVie presents potential upside for investors, supported by an above-average dividend yield of 3.4%, making it an attractive long-term hold [9] - The company's diverse operations provide multiple avenues for growth, although aesthetics sales have declined by 6%, indicating potential for recovery as consumer spending increases [6]

Core Insights - Protagonist Therapeutics (PTGX) shares have increased nearly 7% following the FDA approval of icotrokinra, developed in partnership with Johnson & Johnson (JNJ), for treating moderate-to-severe plaque psoriasis in patients aged 12 and older [1][6] FDA Approval and Product Details - Icotrokinra, marketed as Icotyde in the U.S., is the first targeted oral peptide designed to inhibit the IL-23 receptor [2][4] - The FDA approval was supported by data from four phase III studies within the ICONIC program, demonstrating significant skin clearance and a favorable safety profile [4] Financial Implications - Protagonist will receive a $50 million milestone payment from JNJ, with potential for up to $580 million more in regulatory and sales-based milestones [6][7] - Protagonist is entitled to tiered royalties on global net sales, ranging from 6% to 10%, with an average of approximately 7.25% at $4 billion in annual sales [7] Market Potential - JNJ believes Icotyde has the potential to revolutionize plaque psoriasis treatment as a once-daily oral alternative to existing injectables [8] - Icotyde is also being evaluated for other indications, including psoriatic arthritis and inflammatory bowel diseases, indicating broader market potential [9]